XL PDGFRA BA consists of a green-labeled probe hybridizing proximal to the PDGFRA gene region at 4q12 and an orange-labeled probe hybridizing distal to the PDGFRA gene region at 4q12.

Probe maps are created in accordance with the intended purpose of the product. Solid colored bars do not necessarily indicate that the probe fully covers the indicated genomic region. Therefore, caution is advised when interpreting results generated through off-label use. Probe map details based on UCSC Genome Browser GRCh37/hg19. Map components not to scale. Further information is available on request.

The category ´myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB or FGFR1, or with PCM1/JAK2´ of the revised 4th edition of the WHO classification defines three particular groups with rearrangements in PDGFRA, PDGFRB or FGFR1 and a provisional entity with PCM1/JAK2 rearrangement. The clinical manifestations within this category are numerous and heterogeneous and include myeloproliferative neoplasms, myelodysplastic syndromes as well as de novo or secondary mixed phenotype acute leukemia and lymphomas. Neoplasms with eosinophilia are associated with dysregulated tyrosine kinases, usually as a result of gene fusions. It is of great importance to identify the genes involved because aberrant tyrosine kinases react to tyrosine kinase inhibitors with varying sensitivity. Patients with PDGFRA and PDGFRB rearrangements are responsive to imatinib whereas FGFR1-related diseases are non-responsive. PDGFRA rearrangements are usually associated with chronic eosinophilic leukemia (CEL).
The most frequent PDGFRA-related aberration is the interstitial deletion of the CHIC2 gene with breakpoints in the FIP1L1 and PDGFRA genes. The deletion of a fragment of about 800kb results in the FIP1L1-PDGFRA fusion gene, a constitutively activated tyrosine kinase transforming hematopoietic cells.
In FISH assays, the detection of CHIC2 deletion at 4q12 is a surrogate for the direct detection of the FIP1L1-PDGFRA fusion gene. Translocations with other partner genes, resulting in aberrant tyrosine kinase activity, are known. Involvement of PDGFRA can be detected by FISH break apart strategies.

Clinical Applications

• Chronic Eosinophilic Leukemia (CEL)
• Acute Myelogenous Leukemia (AML)
• Acute Lymphoblastic Leukemia (ALL)

XL PDGFRA BA hybridized to bone marrow cells, one aberrant cell is shown. The expected normal signal pattern of XL PDGFRA BA is two green-orange colocalization/fusion signals representing the two normal PDGFRA loci. Cells with breakaparts typically have one normal green-orange colocalization/fusion signal plus one orange and one green signal clearly separate from one another.

• Cools et al (2003) N Engl J Med 348:1201-1214
• Pardanani et al (2003) Blood 102:3093-3096
• Swerdlow et al (2017) WHO classification of tumors of haematopoietic and lymphoid tissues (revised 4th edition)